Business
SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O’Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. “Liz’s established track record in large, commerci
About this update from Geron Corporation
[{"type":"image","alt":"SpyGlass Pharma, Inc.","displaySize":"","headline":null,"caption":"SpyGlass Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/dc6caa52a627a0de62c10cbc13438f42"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7xhsNFntYl_2ZX0VN_MqYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dc6caa52a627a0de62c10cbc13438f42","width":300,"height":90}},"lazy":false},{"type":"text","content":"","length":6,"tagName":"p"},{"type":"text","content":"ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O’Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management.","length":449,"tagName":"p"},{"type":"text","content":"“Liz’s established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 trials this year,” stated Patrick Mooney, Chief Executive Officer of SpyGlass Pharma. “Her prior experience managing multinational organizations and teams nicely complements our existing Board of Directors’ strengths. We look forward to leveraging Liz’s valued insights, guidance and counsel as SpyGlass advances its novel platform to reimagine glaucoma management for patients with glaucoma and other chronic eye conditions.”","length":671,"tagName":"p"},{"type":"text","content":"“I am excited to join the SpyGlass Board of Directors as the Company prepares to initiate two pivotal Phase 3 trials in patients with moderate open-angle glaucoma or ocular hypertension,” said Ms. O’Farrell. “I was immediately impressed by the compelling multi-year data already generated by SpyGlass’ Drug Delivery Platform, and I look forward to utilizing my deep experience across finance and operational functions to support the SpyGlass team as they advance a longer-duration alternative for chronic ophthalmic conditions.”","length":528,"tagName"...